Updated Phase III MIRASOL Trial Results: Mirvetuximab Soravtansine vs Chemotherapy in Platinum-Resistant Ovarian Cancer with High Folate Receptor-Alpha Expression

home / insights / updated-phase-iii-mirasol-trial-results-mirvetuximab-soravtansine-vs-chemotherapy-in-platinum

Lan Coffman, MD, PhD, discusses results and clinical implications derived from the findings of the phase III MIRASOL trial.

Updated Phase III MIRASOL Trial Results: Mirvetuximab Soravtansine vs Chemotherapy in Platinum-Resistant Ovarian Cancer with High Folate Receptor-Alpha Expression

EP. 1: Updated Phase III MIRASOL Trial Results: Mirvetuximab Soravtansine vs Chemotherapy in Platinum-Resistant Ovarian Cancer with High Folate Receptor-Alpha Expression

November 25th 2024

Dr Coffman breaks down the findings from the phase III MIRASOL trial, and provides insight surrounding the treatment options and potential clinical implications surrounding ovarian cancer treatment.

Watch

© 2024 MJH Life Sciences

All rights reserved.